Valuation: ASKA Pharmaceutical Holdings Co.,Ltd.

Market Cap 56.96B 363M 324M 300M 272M 508M 34.47B 516M 3.58B 1.42B 18.07B 1.36B 1.33B P/E 2027 *
12.2x
P/E 2028 * 10.3x
Enterprise Value 56.96B 363M 324M 300M 272M 508M 34.47B 516M 3.58B 1.42B 18.07B 1.36B 1.33B EV / Sales 2027 *
0.78x
EV / Sales 2028 * 0.76x
Free-Float
64.59%
Yield 2027 *
3.24%
Yield 2028 * 3.49%
09-04 Metagen Therapeutics, Inc. announced that it has received ¥3.71 billion in funding from a group of investors CI
08-04 ASKA Pharmaceutical Holdings Co.,Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
06-25 Declaration of Voting Results by Asuka Pharmaceutical CI
05-27 Dalton Investment strongly oppose conditional activation of countermeasures announced by ASKA Pharmaceutical Holdings on May 25 RE
05-25 Aska pharmaceutical - plan to put to shareholders proposal on countermeasures against potential large-scale share purchase by Dalton and related parties RE
05-11 Asuka Pharmaceutical Opposes Nippon Active Value Fund Plc?s Shareholder Proposal for Board Changes at 2026 Annual Meeting CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Announces Change in Dividend Policy CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Proposes Year-End Dividend for Fiscal Year Ended March 31, 2026, Payable on June 25, 2026; Provides Dividend Guidance for End of Second Quarter of Fiscal Year Ending March 31, 2027 CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2027 CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Announces Retirement of Kazuhiro Chiku as Audit & Supervisory Board Member, Effective June 24, 2026 CI
04-13 FTS AMBROSE HOLDINGS, INC. announced that it has received funding from ASKA Pharmaceutical Holdings Co.,Ltd. CI
03-24 Insilico Medicine And ASKA Pharmaceutical Enter Strategic Research Collaboration For Women's Health CI
1 day-1.13%
1 week-1.57%
Current month-2.43%
1 month-7.51%
3 months-9.31%
6 months-29.52%
Current year-1.57%
1 week 1,996
Extreme 1996
2,049
1 month 1,975
Extreme 1975
2,173
Current year 1,917
Extreme 1917
3,045
1 year 1,917
Extreme 1917
3,045
3 years 1,675
Extreme 1675
3,045
5 years 919
Extreme 919
3,045
10 years 776
Extreme 776
3,045
Manager TitleAgeSince
Chief Executive Officer - -
President 42 2025-06-23
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 74 2025-06-23
Director/Board Member 67 2021-03-31
Director/Board Member 42 2021-03-31
Change 5-day change 1-year change 3-year change Capi.($)
-1.13%-1.57%-8.19%+19.40% 363M
-2.54%+1.31%+54.27%+114.96% 1,135B
-1.42%+3.23%+38.56%+74.44% 636B
+0.16%+0.08%+25.29%+95.23% 505B
-0.31%+3.09%+44.14%+64.80% 378B
-1.34%-0.47%+66.04%+41.00% 358B
-0.68%+2.65%+22.98%+50.39% 295B
-1.20%+3.04%+2.33%+22.86% 266B
-1.79%+1.57%+50.56%+59.08% 237B
-0.73%-0.10%+29.02%+99.67% 193B
Average -1.10%+1.83%+32.50%+64.18% 400.47B
Weighted average by Cap. -1.35%+2.69%+41.02%+79.75%

Financials

2027 *2028 *
Net sales 73.12B 466M 416M 384M 349M 652M 44.25B 663M 4.59B 1.83B 23.19B 1.75B 1.71B 74.96B 478M 426M 394M 357M 669M 45.35B 679M 4.71B 1.87B 23.77B 1.79B 1.76B
Net income 4.67B 29.75M 26.57M 24.55M 22.26M 41.66M 2.83B 42.31M 293M 117M 1.48B 112M 109M 5.52B 35.2M 31.43M 29.05M 26.33M 49.29M 3.34B 50.06M 347M 138M 1.75B 132M 129M
Net Debt - -
Projected Income Statement - Annual - ASKA Pharmaceutical Holdings Co.,Ltd.
Logo ASKA Pharmaceutical Holdings Co.,Ltd.
ASKA Pharmaceutical Holdings Co Ltd is a Japan-based company primarily engaged in the pharmaceutical business. The Company has three business segments. The Pharmaceutical Business segment primarily manufactures and sells prescription pharmaceuticals. The Animal Health Business segment primarily manufactures and sells veterinary medicines, feed additives, and other products. The Overseas Business segment primarily manufactures and sells prescription pharmaceuticals overseas. The Company also engages in clinical testing and medical equipment businesses.
Employees
1,611
Date Price Change Volume
26-10-23 JP¥2,006.00 -1.13% 52,300
26-10-22 JP¥2,029.00 +0.20% 53,700
26-10-21 JP¥2,025.00 +1.05% 67,200
26-10-20 JP¥2,004.00 -1.09% 46,100
26-10-19 JP¥2,026.00 -0.59% 72,700
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - ASKA Pharmaceutical Holdings Co.,Ltd.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2,006.00JPY
Average target price
2,400.00JPY
Spread / Average Target
+19.64%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - ASKA Pharmaceutical Holdings Co.,Ltd.
  1. Stock Market
  2. Stocks
  3. 4886 Stock